Jeff Jay

About Jeff Jay

Jeff is a life sciences transactions attorney who represents pharmaceutical, biotechnology, and medical device companies on transactional, commercial, and corporate matters.

A significant portion of Jeff's practice involves negotiating complex licensing and collaboration arrangements and other strategic alliances. He also frequently advises on mergers and acquisitions and other transactional and commercial matters.

Jeff has previously worked in Freshfields' London office.

Recent work

Licensing & Collaboration Transactions

• Novartis on its (i) strategic collaboration with Vyriad regarding the discovery and development of in vivo chimeric antigen receptor (CAR) T-cell therapies, (ii) co-development and co-commercialization agreement with UCB regarding disease-modifying therapies for Parkinson’s Disease, (iii) collaboration with Cellular Biomedicine Group regarding the CAR-T cell therapy Kymriah® (tisagenlecleucel) in China, (iv) collaboration with Mesoblast regarding remestemcel-L for the treatment of acute respiratory distress syndrome, and (v) collaboration with Sangamo Therapeutics regarding gene regulation therapies directed to neurodevelopmental targets.
• SERB Pharmaceuticals on its license from SFJ Pharmaceuticals to obtain exclusive U.S. rights to bentracimab, a ticagrelor reversal agent.
• Moderna on its collaboration with CARsgen Therapeutics for the development of a combination therapy consisting of an mRNA-based cancer vaccine and an autologous CAR-T therapy.
• Capsida Biotherapeutics on its collaboration with Prevail Therapeutics regarding CNS gene therapies.
• Spark Therapeutics on its collaboration with Senti Biosciences regarding gene therapies directed to specific cell types in the central nervous system, eye, and liver.
• Gilead Sciences on its (i) collaboration with Agenus regarding novel immuno-oncology therapies, (ii) collaboration with Hookipa Biotech regarding immunotherapies directed against hepatitis B virus and human immunodeficiency virus, (iii) collaboration with Tango Therapeutics regarding cancer immunotherapies, and (iv) license with Xencor regarding effector-enhanced, broadly neutralizing anti-HIV antibodies.
• Celgene on the restructuring of its collaboration with Jounce Therapeutics regarding immuno-oncology therapies.

M&A Transactions

• Novartis on its acquisitions of AveXis, Cadent Therapeutics, IFM Tre, MorphoSys AG, and Vedere Bio, as well as its option to acquire (and collaboration with) IFM Due.
• AstraZeneca on its acquisition of Gracell Biotechnologies.
• Roivant Sciences on its $7.1 billion sale of Telavant to Roche and its sale of Dermavant to Organon for up to $1.2 billion.
• SERB Pharmaceuticals on its acquisition of RSDL® (Reactive Skin Decontamination Lotion) kit from Emergent BioSolutions Inc.
• Basilea Pharmaceutica on its acquisition from Pfizer of Fosmanogepix, a clinical-stage antifungal candidate with a novel mechanism of action to treat invasive mold infections.
• Recordati, a portfolio company of CVC Capital Partners, on its acquisition of EUSA Pharma (UK) Limited.
• Celgene on its acquisition of Juno Therapeutics.
• Kite Pharma, a Gilead company, on its option to acquire, and related strategic collaboration with, Gadeta B.V.
• Bausch Health on its option to acquire certain assets of Allegro Ophthalmics.
• Jazz Pharmaceuticals on its acquisition of Cavion.